Cenix is equipped to do high-throughput, genome-scale RNAi screening. The firm believes that its infrastructure and expertise will allow it to help Big pharma and biotech partners sort through masses of targets to find those with biological relevance. Management believes its methodology can also contribute to drug development--RNAi could, for instance, act as a modifier in screening assays, to see whether this additional means of silencing a gene could improve a drug candidate's activity.
Pfotenhauerstrasse 108
D-01307 Dresden, Germany
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.
Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.
Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.
FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.
The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.
FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.
With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.
